| Discovery and clinical introduction of first-in-class imipridone ONC201 JE Allen, CLB Kline, VV Prabhu, J Wagner, J Ishizawa, N Madhukar, ... Oncotarget 7 (45), 74380, 2016 | 140 | 2016 |
| Role of Dopamine Receptors in the Anticancer Activity of ONC201 CLB Kline, MD Ralff, AR Lulla, JM Wagner, PH Abbosh, DT Dicker, ... Neoplasia 20 (1), 80-91, 2018 | 110 | 2018 |
| Current treatment of early breast cancer: adjuvant and neoadjuvant therapy E Miller, HJ Lee, A Lulla, L Hernandez, P Gokare, B Lim F1000Research 3, 2014 | 107 | 2014 |
| Current treatment of early breast cancer: adjuvant and neoadjuvant therapy E Miller, HJ Lee, A Lulla, L Hernandez, P Gokare, B Lim F1000Research 3, 2014 | 107 | 2014 |
| Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 J Wagner, CL Kline, MD Ralff, A Lev, A Lulla, L Zhou, GL Olson, ... Cell Cycle 16 (19), 1790-1799, 2017 | 67 | 2017 |
| Small-molecule prodigiosin restores p53 tumor suppressor activity in chemoresistant colorectal cancer stem cells via c-jun-mediated δnp73 inhibition and p73 activation VV Prabhu, B Hong, JE Allen, S Zhang, AR Lulla, DT Dicker, WS El-Deiry Cancer research 76 (7), 1989-1999, 2016 | 63 | 2016 |
| miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell cycle arrest in colon cancer cells AR Lulla, MJ Slifker, Y Zhou, A Lev, MB Einarson, DT Dicker, WS El-Deiry Cancer Research, canres. 1767.2017, 2017 | 53 | 2017 |
| Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP A Lev, AR Lulla, J Wagner, MD Ralff, JB Kiehl, Y Zhou, CH Benes, ... Oncotarget 8 (47), 81776, 2017 | 44 | 2017 |
| ONC201: a new treatment option being tested clinically for recurrent glioblastoma MD Ralff, AR Lulla, J Wagner, WS El-Deiry Translational cancer research 6 (Suppl 7), S1239, 2017 | 42 | 2017 |
| Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies VV Prabhu, MK Talekar, AR Lulla, CLB Kline, L Zhou, J Hall, ... Cell Cycle, 1-11, 2018 | 40 | 2018 |
| Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors VV Prabhu, AR Lulla, NS Madhukar, MD Ralff, D Zhao, CLB Kline, ... PLoS One 12 (8), e0180541, 2017 | 40 | 2017 |
| ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer A Lev, AR Lulla, BC Ross, MD Ralff, PB Makhov, DT Dicker, WS El-Deiry Molecular Cancer Research 16 (5), 754-766, 2018 | 25 | 2018 |
| Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer A Lev, S Deihimi, E Shagisultanova, J Xiu, AR Lulla, DT Dicker, ... Cancer biology & therapy 18 (9), 694-704, 2017 | 17 | 2017 |
| P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9 X Tian, N Ahsan, A Lulla, A Lev, P Abbosh, DT Dicker, S Zhang, ... Neoplasia 23 (3), 304-325, 2021 | 15 | 2021 |
| High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma HAF Stessman, A Lulla, T Xia, A Mitra, T Harding, A Mansoor, CL Myers, ... Leukemia 28 (11), 2263-2267, 2014 | 13 | 2014 |
| CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA LJ Hernandez-Borrero, S Zhang, A Lulla, DT Dicker, WS El-Deiry Cell Cycle, 1-11, 2018 | 9 | 2018 |
| Bcl-2 Protein Targeting by the p53/p21 Complex LJ Hernandez Borrero, R Sikder, A Lulla, P Gokare, PR Del Valle, X Tian, ... Cancer Research 78 (10), 2770-2771, 2018 | 4 | 2018 |
| MMR-deficiency and BRCA2/EGFR/NTRK mutations P Gokare, AR Lulla, WS El-Deiry Aging (Albany NY) 9 (8), 1849, 2017 | 4 | 2017 |
| Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Research, 3, 198 E Miller, HJ Lee, A Lulla, L Hernandez, P Gokare, B Lim | 4 | 2014 |
| LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers AR Lulla, S Akli, C Karakas, MJ Ha, NW Fowlkes, Y Mitani, T Bui, J Wang, ... Oncogenesis 10 (5), 40, 2021 | 2 | 2021 |
Wafik El-DeiryAssociate Dean, Warren Alpert Medical School, Brown UniversityVerified email at brown.edu
